NASDAQ:CDLXCardlytics Stock Price, Forecast & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDLX stock has increased by 72.7% and is now trading at $79.17. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) announced its earnings results on Monday, May, 11th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.09. The firm earned $45.51 million during the quarter, compared to the consensus estimate of $42.97 million. Cardlytics had a negative return on equity of 19.42% and a negative net margin of 11.08%. The company's quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.23) EPS. View Cardlytics' earnings history.

6 brokerages have issued twelve-month price objectives for Cardlytics' shares. Their forecasts range from $26.00 to $75.00. On average, they expect Cardlytics' stock price to reach $51.83 in the next year. This suggests that the stock has a possible downside of 34.5%. View analysts' price targets for Cardlytics.

Press coverage about CDLX stock has trended very negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cardlytics earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Cardlytics.

Some companies that are related to Cardlytics include Weibo (WB), 58.com (WUBA), Legend Biotech (DADA), HUYA (HUYA), Switch (SWCH), DouYu International (DOYU), Medallia (MDLA), SVMK (SVMK), 21Vianet Group (VNET), Pluralsight (PS), Tripadvisor (TRIP), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN) and Health Catalyst (HCAT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $79.17.

Cardlytics has a market capitalization of $2.14 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]